All In Biotech

Drug Trial Radar · NCT07033481

Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)

Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Oct 2, 2025

Primary completion

Sep 2026

Study completion Oct 2026

Sponsor

Lead sponsor
EIP Pharma IncIndustry
Sponsor type
Industry
Collaborators
CervoMed, Inc.
First posted
Jun 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.

Conditions

  • Nonfluent Variant Primary Progressive Aphasia (nfvPPA)

Interventions

  • NeflamapimodDrug

    Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α)

  • PlaceboDrug

    Placebo is a capsule that looks just like neflamapimod but without the active ingredients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events and Serious Adverse Events.Time frame: Baseline to Week 36

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Mayo Clinic

    Rochester, Minnesota

  • Columbia University

    New York, New York

  • The Ohio State University

    Columbus, Ohio

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Windsor Research Unit, Fulbourn Hospital

    Cambridge, United Kingdom

  • Clinical Ageing Research Unit, Campus for Ageing and Vitality, Biomedical Research Building

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.